2 news · updated Sep 1, 2026

Samsung Buys PolyPeptide

2026-09-01

Samsung Biologics launches $2B rights offering to fund expansion

Samsung Biologics launched a $2.1 billion rights offering to acquire PolyPeptide Group and expand Bio Campus II capacity. The investment targets peptide-based therapeutics and antibodies, aiming to re

chemweek · 2026-09-01 15:08 UTC

2026-07-22

Samsung Makes $1.8 Billion Bet on Peptide Production

Samsung Biologics launched a $1.8 billion bid for Swiss peptide maker PolyPeptide Group, expanding its contract manufacturing business into the fast-growing peptide market driven by GLP-1 drugs.

cen · 2026-07-22 00:00 UTC

Samsung Buys PolyPeptide

Samsung Biologics launches $2B rights offering to fund expansion

Samsung Makes $1.8 Billion Bet on Peptide Production

Media coverage (2)

Related topics